RxDoctor Payments Data

Douglas Bunting, MD

Nephrology · Pensacola, FLNPI 1407840440

Payments from drug & device makers

$2,941in general payments, 2019–2025

Across 140 payments — averaging $21.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bard Peripheral Vascular, Inc.$402
  • Amgen$362
  • AstraZeneca$352
  • Travere Therapeutics, Inc.$343
  • Otsuka America Pharmaceutical, Inc.$298
  • OPKO Pharmaceuticals, LLC$277
  • plus $908 from 17 others

What the payments were for

  • Food & beverage$2,927100%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,941 in reported general payments places this provider in the 60th percentile of 756 nephrology providers in Florida.

See all nephrology providers in Florida

Medicare billing

Part B allowed, 2024
$464,446
Medicare patients
977
Services billed
3,943

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JynarqueTolvaptan11$213,606
FarxigaDapagliflozin Propanediol165$150,214
JardianceEmpagliflozin75$65,076
LokelmaSodium Zirconium Cyclosilicate49$29,857
KerendiaFinerenone16$16,446
RayaldeeCalcifediol19$15,471
Sevelamer Carbonate30$6,551
Calcitriol284$3,790
Calcium Acetate28$2,414
Bumetanide47$1,819
Losartan Potassium182$1,435
Furosemide185$1,371
Atorvastatin Calcium103$1,146
Doxazosin Mesylate108$931
Lisinopril113$864

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Jynarque$298$213,60611 claims
AstraZenecaFarxiga, Lokelma$352$180,071214 claims
BayerKerendia$149$16,44616 claims
OPKO Pharmaceuticals, LLCRayaldee$277$15,47119 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 756 nephrology providers in Florida.

Other nephrology in Pensacola

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →